Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Harvard Medical School, and Division of Immunology, Boston Children’s Hospital, Boston, Massachusetts.
Mol Cancer Ther (2024) 23 (10): 1365.
A $6.4 billion lawsuit against Bristol Myers Squibb (BMS) was dismissed on Monday. The suit alleged that BMS purposely delayed approval of drugs developed by Celgene to avoid paying $6.4 billion to ...
The University of Texas MD Anderson Cancer Center, Houston, TX, United States ...
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Goodman Cancer Institute, McGill University, Montréal, Canada.
Major Finding: Coagulation factor X (FX) promotes proliferation and androgen independence in prostate cancer. Concept: Immunosuppressive neutrophils secrete FX, which binds PAR2 on PCa cells and ...
The development of second-generation covalent “off”-state KRAS G12C inhibitors is taking off. Two candidates, D3S-001 and divarasib, highlighted at the 2024 ESMO Congress, show better efficacy, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback